Monday, May 05, 2025 5:26:36 PM
On the other hand the June 2021 increase occurred during a flurry of PR's including the PD data. Short interest went up 2 MM shares as traders realized they reported an endpoint related to the primary but not the actual primary endpoint and correctly assuming AVXL would raise funds during teh upturn. .
Date | Short Interest (Shares) | Price (USD) | Days to Cover | % of Float Shorted
-----------|-------------------------|-------------|---------------|--------------------
2021-12-31 | 4,500,000 | 17.34 | 5.3 | N/A
2021-12-15 | 4,830,000 | 19.14 | 5.8 | N/A
2021-11-30 | 4,810,000 | 19.40 | 5.9 | N/A
2021-11-15 | 4,410,000 | 21.50 | 5.5 | 9.9%
2021-10-29 | 5,130,000 | 18.74 | 6.1 | 11.5%
2021-10-15 | 5,110,000 | 17.52 | 5.3 | 11.5%
2021-09-30 | 5,820,000 | 17.95 | 4.8 | 13.1%
2021-09-15 | 5,630,000 | 17.07 | 3.2 | N/A
2021-08-31 | 5,960,000 | 19.49 | 2.3 | N/A
2021-08-13 | 6,940,000 | 19.55 | 2.6 | N/A
2021-07-30 | 6,690,000 | 17.95 | 2.5 | N/A
2021-07-15 | 7,600,000 | 22.16 | 3.1 | N/A
2021-06-30 | 8,770,000 | 22.86 | 3.7 | 12.5%
2021-06-15 | 7,020,000 | 17.34 | 3.8 | 10.4%
2021-05-28 | 6,540,000 | 12.45 | 5.7 | 9.7%
2021-05-14 | 6,560,000 | 10.16 | 5.0 | N/A
2021-04-30 | 6,900,000 | 12.25 | 4.2 | N/A
2021-04-15 | 6,390,000 | 12.87 | 1.6 | N/A
2021-03-31 | 5,610,000 | 14.03 | 1.4 | N/A
2021-03-15 | 3,600,000 | 14.03 | 0.9 | N/A
2021-02-26 | 3,960,000 | 13.06 | 1.0 | N/A
2021-02-12 | 4,010,000 | 12.71 | 1.1 | N/A
2021-01-29 | 5,260,000 | 6.34 | 1.4 | N/A
2021-01-15 | 5,580,000 | 5.92 | 4.3 | N/A
above data courtesy of ChatGPT
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
